{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:39:26Z","timestamp":1793410766826,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,14]]},"DOI":"10.7759\/cureus.103591","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:02:41Z","timestamp":1771077761000},"source":"Crossref","is-referenced-by-count":3,"title":["Statin-Induced Hyper-Acute Reversible Liver Failure: A Case Report"],"prefix":"10.7759","author":[{"given":"Abdulaziz A","family":"AlTurki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"AlQahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkreem A","family":"Alnasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meshal M","family":"AlTalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S","family":"AlHamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2025","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"An assessment by the Statin Liver Safety Task Force: 2014\u00a0update","volume":"8","author":"Bays H","year":"2014","unstructured":"Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014\u00a0update. J Clin Lipidol. 2014, 8:S47-57. 10.1016\/j.jacl.2014.02.011","journal-title":"J Clin Lipidol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033743","article-title":"Fatal hepatic failure following atorvastatin treatment: a case report","volume":"102","author":"Wang H","year":"2023","unstructured":"Wang H, Liu S, Zhou C, Fu Y. Fatal hepatic failure following atorvastatin treatment: a case report. Medicine (Baltimore). 2023, 102:e33743. 10.1097\/MD.0000000000033743","journal-title":"Medicine (Baltimore)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bj\u00f6rnsson E","year":"2005","unstructured":"Bj\u00f6rnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005, 42:481-9. 10.1002\/hep.20800","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade RJ","year":"2005","unstructured":"Andrade RJ, Lucena MI, Fern\u00e1ndez MC, et al.. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005, 129:512-21. 10.1016\/j.gastro.2005.05.006","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani N","year":"2008","unstructured":"Chalasani N, Fontana RJ, Bonkovsky HL, et al.. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008, 135:1924-34, 1934.e1-4. 10.1053\/j.gastro.2008.09.011","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2006.04.013","article-title":"Atorvastatin associated liver disease","volume":"38","author":"Clarke AT","year":"2006","unstructured":"Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis. 2006, 38:772-7. 10.1016\/j.dld.2006.04.013","journal-title":"Dig Liver Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-827800464-1.","article-title":"Fatal liver failure with atorvastatin","volume":"39","author":"Perger L","year":"2003","unstructured":"Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003, 39:1095-7. 10.1016\/s0168-827800464-1.","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-934301178-6.","article-title":"Multiorgan failure induced by atorvastatin","volume":"113","author":"Sreenarasimhaiah J","year":"2002","unstructured":"Sreenarasimhaiah J, Shiels P, Lisker-Melman M. Multiorgan failure induced by atorvastatin. Am J Med. 2002, 113:348-9. 10.1016\/s0002-934301178-6.","journal-title":"Am J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law M","year":"2006","unstructured":"Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006, 97:52-60C. 10.1016\/j.amjcard.2005.12.010","journal-title":"Am J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci H","year":"2013","unstructured":"Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013, 6:390-9. 10.1161\/CIRCOUTCOMES.111.000071","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/157488609789006949","article-title":"Adverse effects of statins - mechanisms and consequences","volume":"4","author":"Be\u0142towski J","year":"2009","unstructured":"Be\u0142towski J, W\u00f3jcicka G, Jamroz-Wi\u015bniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf. 2009, 4:209-28. 10.2174\/157488609789006949","journal-title":"Curr Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver","volume":"41","author":"Chalasani N","year":"2005","unstructured":"Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005, 41:690-5. 10.1002\/hep.20671","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27157. Epub 2014 May 13.","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo MW","year":"2014","unstructured":"Russo MW, Hoofnagle JH, Gu J, et al.. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014, 60:679-86. 10.1002\/hep.27157. Epub 2014 May 13.","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer DO","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, et al.. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2021, 52:e364-467. 10.1161\/STR.0000000000000375","journal-title":"Stroke"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.493106","article-title":"Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"38","author":"Amarenco P","year":"2007","unstructured":"Amarenco P, Goldstein LB, Szarek M, et al.. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007, 38:3198-204. 10.1161\/STROKEAHA.107.493106","journal-title":"Stroke"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2396987319838100","article-title":"Treat stroke to target trial design: first trial comparing two LDL targets in patients with atherothrombotic strokes","volume":"4","author":"Amarenco P","year":"2019","unstructured":"Amarenco P, Kim JS, Labreuche J, et al.. Treat stroke to target trial design: first trial comparing two LDL targets in patients with atherothrombotic strokes. Eur Stroke J. 2019, 4:271-80. 10.1177\/2396987319838100","journal-title":"Eur Stroke J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020, 41:111-88. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462610-statin-induced-hyper-acute-reversible-liver-failure-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:02:41Z","timestamp":1771077761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462610-statin-induced-hyper-acute-reversible-liver-failure-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.103591","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}